Aprepitant as a premedication for prevention of post operative nausea and vomiting (PONV).
Not Applicable
- Conditions
- Health Condition 1: O- Medical and Surgical
- Registration Number
- CTRI/2021/11/037883
- Lead Sponsor
- JSS MEDICAL COLLEGE AND HOSPITA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Adults of ASA Physical status class I/II aged 18-60 years undergoing laparoscopic surgeries.
Exclusion Criteria
Patients already on treatment with anti-emetics, steroid medication, or any other drug known to cause emesis currently or in the immediate past
Patients with known hypersensitivity to ondansetron or aprepitant
Pregnant or nursing mothers.
Hepatic, renal or cardiac insufficiency. Vomiting within 24 hours before surgery or of any organic aetiology.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the efficacy between Ondansetron and Aprepitant for prevention of PONV in patients undergoing laparoscopic surgeries.Timepoint: To assess the efficacy of aprepitant following surgery with no incidence of PONV immediately after surgery, 2hours, 4hours, 6hours, 12hours and 24hours following surgery. <br/ ><br>
- Secondary Outcome Measures
Name Time Method 1) To determine the safety of aprepitant as a part of antiemetic prophylaxis. <br/ ><br>2) To determine the requirement of rescue antiemetics post-operatively. <br/ ><br>Timepoint: Post operative usage of rescue antiemetics and adverse events noted immediately following surgery, after 2 hours, 4 hours, 6 hours, 12 hours and 24 hours.